DarioHealth (DRIO)
Market Price (3/30/2026): $8.1 | Market Cap: $54.7 MilSector: Health Care | Industry: Health Care Technology
DarioHealth (DRIO)
Market Price (3/30/2026): $8.1Market Cap: $54.7 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Telehealth Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -94%, 3Y Excs Rtn is -152% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -164% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -17%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.6%, Rev Chg QQuarterly Revenue Change % is -31% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 42% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -116%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -117% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -80% | ||
| High stock price volatilityVol 12M is 2024% | ||
| Key risksDRIO key risks include [1] substantial doubt about its ability to continue as a going concern due to significant operating losses and a breached financial covenant, Show more. |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Telehealth Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -94%, 3Y Excs Rtn is -152% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -164% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -17%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.6%, Rev Chg QQuarterly Revenue Change % is -31% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 42% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -116%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -117% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -80% |
| High stock price volatilityVol 12M is 2024% |
| Key risksDRIO key risks include [1] substantial doubt about its ability to continue as a going concern due to significant operating losses and a breached financial covenant, Show more. |
Qualitative Assessment
AI Analysis | Feedback
DarioHealth (DRIO) stock has lost about 30% since 11/30/2025 because of the following key factors:
1. DarioHealth experienced a significant full-year revenue decline in 2025, with revenue dropping to $22.4 million from $27.0 million in 2024. This decrease was primarily attributed to the non-renewal of a single legacy client from the Twill acquisition and a significant scope change with a large national health plan client, acting as a one-time headwind.
2. The company reported an increased non-GAAP net loss in the fourth quarter of 2025. The non-GAAP net loss for Q4 2025 grew by 32% to $6.5 million, compared to $4.9 million in Q4 2024. This widening net loss in the most recent quarter likely contributed to negative investor sentiment.
Show more
1. DarioHealth experienced a significant full-year revenue decline in 2025, with revenue dropping to $22.4 million from $27.0 million in 2024. This decrease was primarily attributed to the non-renewal of a single legacy client from the Twill acquisition and a significant scope change with a large national health plan client, acting as a one-time headwind.
2. The company reported an increased non-GAAP net loss in the fourth quarter of 2025. The non-GAAP net loss for Q4 2025 grew by 32% to $6.5 million, compared to $4.9 million in Q4 2024. This widening net loss in the most recent quarter likely contributed to negative investor sentiment.
Show more
Stock Movement Drivers
Fundamental Drivers
The -32.1% change in DRIO stock from 11/30/2025 to 3/29/2026 was primarily driven by a -53.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.94 | 8.11 | -32.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 25 | 22 | -9.6% |
| P/S Multiple | 1.5 | 2.5 | 61.8% |
| Shares Outstanding (Mil) | 3 | 7 | -53.6% |
| Cumulative Contribution | -32.1% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| DRIO | -32.1% | |
| Market (SPY) | -5.3% | -12.2% |
| Sector (XLV) | -8.7% | -5.3% |
Fundamental Drivers
The -14.7% change in DRIO stock from 8/31/2025 to 3/29/2026 was primarily driven by a -63.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.51 | 8.11 | -14.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 27 | 22 | -17.6% |
| P/S Multiple | 0.9 | 2.5 | 182.0% |
| Shares Outstanding (Mil) | 2 | 7 | -63.3% |
| Cumulative Contribution | -14.7% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| DRIO | -14.7% | |
| Market (SPY) | 0.6% | 0.1% |
| Sector (XLV) | 5.2% | -8.1% |
Fundamental Drivers
The -41.7% change in DRIO stock from 2/28/2025 to 3/29/2026 was primarily driven by a -70.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.92 | 8.11 | -41.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 23 | 22 | -3.0% |
| P/S Multiple | 1.2 | 2.5 | 100.9% |
| Shares Outstanding (Mil) | 2 | 7 | -70.1% |
| Cumulative Contribution | -41.7% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| DRIO | -41.7% | |
| Market (SPY) | 9.8% | 2.3% |
| Sector (XLV) | -2.1% | -1.9% |
Fundamental Drivers
The -91.2% change in DRIO stock from 2/28/2023 to 3/29/2026 was primarily driven by a -83.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 92.00 | 8.11 | -91.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 27 | 22 | -16.8% |
| P/S Multiple | 3.9 | 2.5 | -37.7% |
| Shares Outstanding (Mil) | 1 | 7 | -83.0% |
| Cumulative Contribution | -91.2% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| DRIO | -91.2% | |
| Market (SPY) | 69.4% | 2.3% |
| Sector (XLV) | 18.4% | -0.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DRIO Return | -9% | -67% | -60% | -54% | -28% | -26% | -97% |
| Peers Return | -50% | -71% | -4% | -55% | -21% | -13% | -96% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| DRIO Win Rate | 50% | 17% | 42% | 33% | 25% | 33% | |
| Peers Win Rate | 28% | 31% | 50% | 31% | 34% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| DRIO Max Drawdown | -27% | -73% | -77% | -62% | -97% | -34% | |
| Peers Max Drawdown | -55% | -73% | -36% | -63% | -33% | -29% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, HNGE, OMDA, AMWL, GDRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | DRIO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.7% | -25.4% |
| % Gain to Breakeven | 2942.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -64.1% | -33.9% |
| % Gain to Breakeven | 178.3% | 51.3% |
| Time to Breakeven | 134 days | 148 days |
| 2018 Correction | ||
| % Loss | -95.7% | -19.8% |
| % Gain to Breakeven | 2207.7% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to TDOC, HNGE, OMDA, AMWL, GDRX
In The Past
DarioHealth's stock fell -96.7% during the 2022 Inflation Shock from a high on 2/12/2021. A -96.7% loss requires a 2942.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About DarioHealth (DRIO)
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
AI Analysis | Feedback
DarioHealth is like a Livongo (now part of Teladoc Health) for a broader range of chronic conditions, encompassing metabolic health, musculoskeletal, and behavioral health.
Imagine a digital health coach like Noom, but expanded to manage multiple chronic conditions such as diabetes, hypertension, and musculoskeletal pain, integrating smart devices and personalized care.
AI Analysis | Feedback
- Dario's Metabolic Solutions: Digital therapeutics designed to address metabolic health needs, including diabetes, hypertension, and weight management.
- Dario Musculoskeletal (MSK): Solutions aimed at preventing and treating common musculoskeletal conditions.
- Dario's Behavioral Health Solution: Provides optimized access to evidence-based care for behavioral health.
- DarioEngage Platform: A proprietary care management platform facilitating chronic condition management.
- Connected Health Devices: Includes smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, and biofeedback sensor devices for health monitoring.
- Device-Specific Disposables: Consumable supplies such as test strip cartridges and lancets for monitoring systems.
- Diabetes Management Programs: Comprehensive programs offering lifestyle changes, healthy eating guidance, advanced tracking, and live coaching for diabetes patients.
AI Analysis | Feedback
DarioHealth (DRIO) primarily sells its digital health solutions to other companies rather than directly to individual consumers. Its major customer categories include:
- Employers: Companies that contract with DarioHealth to offer digital health and chronic condition management programs as a benefit to their employees.
- Health Plans and Payers: Insurance companies, self-insured employers, and other benefit administrators that integrate DarioHealth's solutions into their offerings for their members or covered populations.
- Provider Systems: Hospitals, clinics, and integrated delivery networks that utilize DarioHealth's platform and solutions to enhance patient care, management, and engagement for individuals with chronic conditions.
AI Analysis | Feedback
nullAI Analysis | Feedback
Erez Raphael, Chief Executive Officer
Erez Raphael has served as the Chief Executive Officer and a Director of DarioHealth Corp. since 2018, having been appointed CEO in August 2013. Before his tenure at DarioHealth, Mr. Raphael was the Head of Business Operations at Nokia Siemens Networks Israel Ltd. from 2010 to 2012 and held a Principal role at Amdocs Ltd. from 1998 to 2011. He holds an undergraduate degree from the University of Haifa. Under his leadership, DarioHealth evolved from a diabetes management platform, expanding into hypertension and musculoskeletal care through acquisitions, with a strategic focus on building an integrated chronic condition management solution and shifting towards a business-to-business model with health plans and employers.
Chen Franco-Yehuda, Chief Financial Officer
Chen Franco-Yehuda is slated to become DarioHealth's Chief Financial Officer, Treasurer, and Secretary, effective May 15, 2025. She brings extensive financial leadership experience, with a strong background in corporate finance, capital markets, and strategic growth initiatives within publicly traded companies in the healthcare and life sciences sectors. Prior to joining DarioHealth, Ms. Franco-Yehuda was the Chief Financial Officer, Treasurer, and Secretary at Pluri Inc. (Nasdaq, TASE: PLUR), a global biotech company. In her previous role, she was instrumental in leading financial strategy, investor relations, legal affairs, significant cross-border transactions, securing substantial capital through public and private fundraising, executing non-dilutive funding agreements, and driving merger and acquisition initiatives.
Steven Nelson, President & Chief Commercial Officer
Steven Nelson is the President and Chief Commercial Officer at DarioHealth. He is responsible for developing and executing strategies to drive rapid commercialization, overseeing the company's global commercial activities, including growth strategy, sales, client management, marketing, strategic partnerships, and expansion into new markets. Mr. Nelson possesses over two decades of experience in building and scaling technology-centric healthcare companies. Most recently, he served as the Chief Executive Officer and President of Contigo Health, a multi-faceted collaborator for healthcare providers, plans, and employers.
Lara Dodo, Chief Operations Officer
Lara Dodo serves as the Chief Operations Officer at DarioHealth. She is a seasoned commercial and operations executive with over 20 years of experience across various industries, including digital health, health-tech, technology/software, professional services, not-for-profit, and manufacturing. Her career encompasses Senior Leadership and C-Level roles in both start-up and Fortune 1000 organizations. Previously, Ms. Dodo was the Chief Growth and Operating Officer at Newtopia, where she led teams to expand market share and develop products and services that catered to clients. She also had an opportunity to lead a gaming company as CEO. She holds a Bachelor of Commerce from the University of South Africa.
Omar Manejwala M.D., Chief Medical Officer
Dr. Omar Manejwala is the Chief Medical Officer at DarioHealth. He is recognized as a leading expert in behavior change, particularly concerning chronic diseases. His career is distinguished by the development, piloting, and commercialization of scalable solutions that foster lasting behavior change. In his role at DarioHealth, Dr. Manejwala oversees clinical solutions, conducts clinical research, evaluates clinical partnerships, and defines clinical product and sales strategies. Prior to joining DarioHealth, he was the Chief Medical Officer of Catasys (now OnTrak, Nasdaq: OTRK), where he was instrumental in developing the product from its initial stages to commercial scale, securing contracts with major health plans across 28 states, which contributed to Catasys's valuation reaching approximately $1.5 billion at its peak. Dr. Manejwala also served as Medical Director at the Hazelden Foundation. He is board-certified in Psychiatry, Addiction Medicine, and Medical Management, and holds an M.D. from the University of Maryland School of Medicine and an MBA from the University of Virginia's Darden School of Business. He is also the author of the best-selling book "Craving: Why We Can't Seem to Get Enough".
AI Analysis | Feedback
```htmlKey Business Risks for DarioHealth (DRIO)
- Financial Stability and Operating Losses: DarioHealth has a history of significant operating losses and limited financial resources, raising concerns about its long-term sustainability and ability to attract future investment for growth and development. The company has experienced challenges with cash burn and has been noted to have less than a year of cash runway.
- Intense Competition in the Digital Health Market: The digital health sector in which DarioHealth operates is highly competitive, crowded, and rapidly evolving. DarioHealth competes against a wide array of companies, including telehealth giants and specialized startups, many of whom possess significantly greater financial resources and market reach, making it challenging for DarioHealth to maintain its market position and profitability.
- Regulatory and Compliance Challenges: Changes in healthcare regulations could materially impact DarioHealth's business model and growth prospects, potentially leading to increased compliance costs and operational hurdles. Furthermore, the company has faced specific compliance issues, such as needing an extension to meet Nasdaq's minimum bid price requirements for continued listing.
AI Analysis | Feedback
- Large technology companies (e.g., Apple, Google, Amazon) are increasingly expanding their presence in comprehensive digital health and chronic condition management. These companies possess immense capital, vast user bases, advanced AI capabilities, and existing platform ecosystems that could integrate competing digital therapeutic solutions across metabolic health, musculoskeletal care, and behavioral health, directly challenging DarioHealth's multi-condition offerings.
- Established medical device and pharmaceutical companies are rapidly integrating holistic digital therapeutics and patient support programs into their core product lines. Companies with existing market dominance in diabetes devices (e.g., Abbott, Dexcom, Medtronic) or pharmaceuticals (e.g., Novo Nordisk, Eli Lilly) are leveraging their brand recognition, regulatory experience, and deep relationships with healthcare providers and patients to offer comprehensive digital solutions that directly compete with DarioHealth's specific condition management programs.
AI Analysis | Feedback
DarioHealth (DRIO) operates within several significant addressable markets for its digital therapeutics products and services:
- Overall Digital Therapeutics Market:
- The global addressable market for digital therapeutics is estimated at approximately $108 billion.
- In the United States, DarioHealth estimates an annual addressable market of $72 billion for its chronic condition management platform.
- The global digital therapeutics market was valued at USD 7.7 billion in 2024 and is projected to reach USD 75.4 billion by 2034.
- The U.S. digital therapeutics market was valued at USD 3.72 billion in 2025 and is expected to reach USD 24.09 billion by 2035.
- Dario's Metabolic Solutions (Diabetes, Hypertension, and Weight Management):
- Digital Diabetes Management:
- The global digital diabetes management market was valued at USD 31.90 billion in 2024 and is projected to cross approximately USD 171.63 billion by 2034.
- The U.S. digital diabetes management market was estimated at USD 9.85 billion in 2024 and is predicted to be worth around USD 54.07 billion by 2033.
- Digital Health for Obesity:
- The global digital health for obesity market was valued at USD 59.4 billion in 2024 and is estimated to grow to USD 441.2 billion by 2034.
- The global digital health for obesity market was valued at USD 71.67 billion in 2025 and is predicted to reach USD 619.66 billion by 2035.
- The U.S. digital health for obesity market is anticipated to dominate the North American market, exhibiting a CAGR of 21.8% during the forecast period.
- The global GLP-1 market, relevant for weight management with medication support, is projected to reach $100 billion globally by 2030, with $44 billion specifically for U.S. obesity treatment.
- Hypertension: Specific market sizing for digital therapeutics solely for hypertension was not identified, but it is encompassed within broader metabolic health and chronic condition management digital therapeutics markets.
- Digital Diabetes Management:
- Dario Musculoskeletal (MSK):
- The global digital health for musculoskeletal care market is expected to reach USD 11.8 billion by 2031.
- The global digital musculoskeletal (MSK) care market is estimated to be valued at USD 5.10 billion in 2025 and is expected to reach USD 15.92 billion by 2032.
- North America held a 39% revenue share in the digital health for musculoskeletal care market in 2023.
- Dario's Behavioral Health Solution:
- The global digital behavioral health market was calculated at USD 27.9 billion in 2024 and is projected to reach approximately USD 153.85 billion by 2034.
- The global digital therapeutics in mental health market was valued at USD 3.03 billion in 2024 and is expected to reach USD 13.58 billion by 2032.
- North America held a major revenue share of the global digital behavioral health market in 2024.
AI Analysis | Feedback
DarioHealth (DRIO) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- Expansion of the Business-to-Business-to-Consumer (B2B2C) Segment: DarioHealth anticipates significant revenue growth from its core B2B2C business, which focuses on employers and health plans. This segment saw a 400% year-over-year increase in recurring revenue in Q4 2024 and contributed to a 32.9% increase in total revenue for the full year 2024. The company is actively acquiring new clients, having secured 36 new employer and health plan contracts in 2024, bringing its total client base to 83 organizations, with a forecast of 50% net client growth in 2025. This channel is described as the "engine of the revenue base" and is expected to accelerate through 2025.
- Strategic Acquisition and Integration of Twill: The acquisition of Twill in February 2024 is a pivotal driver, enabling DarioHealth to offer one of the most comprehensive digital health platforms for chronic conditions. This acquisition immediately expanded DarioHealth's market access to major health plans and Fortune 100 employers. The integration is expected to accelerate the path to profitability, enhance gross margins, and create significant cross-sell opportunities within the combined client base, which includes major national health plans and large national employers.
- Introduction and Expansion of GLP-1 Digital Health Solutions: DarioHealth recently announced an Oral GLP-1 Digital Health Solution with Precision Behavioral Support. The company views its products as fundamentally complementing the growing GLP-1 market opportunity, which is expanding beyond weight loss into broader chronic care management. This new offering positions DarioHealth to capitalize on the increasing demand for solutions that support GLP-1 cost management.
- Growth in Commercial Strategic Partnerships (Pharma): DarioHealth expects to see growth in its "Commercial Strategic" revenue stream, which is primarily derived from partnerships with pharmaceutical companies such as Sanofi, Merck, and Eli Lilly. There is anticipated growth in 2024 and 2025 due to demand for the integrated Dario-Twill offering from pharma partners. In Q3 2024, DarioHealth secured two new deals, including one with a top global pharma company, as it transforms this channel into a platform-based recurring revenue model.
- Leveraging AI and its Multi-Condition Platform: The company's multi-condition platform, addressing five chronic conditions, is a key differentiator in a market seeking consolidated, value-driven solutions. DarioHealth plans to integrate AI to further enhance outcomes, improve operational efficiencies, and unlock new revenue streams. Advancements in its AI-powered platform and the expanded product portfolio post-Twill acquisition align with the market shift towards whole-person care.
AI Analysis | Feedback
Share Issuance
- DarioHealth completed a private placement of convertible preferred stock, raising $22.4 million in February 2024.
- In January 2025, the company raised $25.6 million through a private placement of convertible preferred stock, with participation from existing shareholders and accredited healthcare investors.
- A private placement for the sale of 2,713,180 shares of common stock was announced in September 2025, expected to generate approximately $17.5 million in gross proceeds.
Inbound Investments
- DarioHealth secured a $22.4 million investment through a private placement of convertible preferred stock in February 2024.
- In January 2025, the company received $25.6 million from a private placement of convertible preferred stock, with significant investment from existing shareholders and prominent accredited healthcare investors.
- A private placement in September 2025 was anticipated to bring in approximately $17.5 million in gross proceeds from the sale of common stock.
Outbound Investments
- DarioHealth acquired Twill, Inc. in February 2024 for a consideration of $10 million in cash and approximately 10 million shares of common stock in the form of pre-funded warrants.
- In May 2021, DarioHealth acquired PsyInnovations, Inc. (dba wayForward) for an aggregate consideration of $30.0 million, which included $6.0 million in cash and up to $24.0 million in shares of common stock (inclusive of a $5.0 million earn-out).
- DarioHealth completed the acquisition of Upright in January 2021 for $31 million.
Capital Expenditures
- DarioHealth's capital expenditures for the fourth quarter of 2024 were $0.021 million.
- Capital expenditures in the first quarter of 2025 totaled $0.031 million.
- For the second quarter of 2025, capital expenditures were $0.044 million.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| DarioHealth Earnings Notes | 12/16/2025 | |
| Is DarioHealth Stock Built to Withstand More Downside? | 10/17/2025 | |
| Day 5 of Gains Streak for DarioHealth Stock with 122% Return (vs. -13% YTD) [9/25/2025] | 09/26/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to DRIO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.70 |
| Mkt Cap | 0.7 |
| Rev LTM | 424 |
| Op Inc LTM | -71 |
| FCF LTM | 53 |
| FCF 3Y Avg | 32 |
| CFO LTM | 93 |
| CFO 3Y Avg | 66 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -0.5% |
| Rev Chg 3Y Avg | 1.4% |
| Rev Chg Q | -0.8% |
| QoQ Delta Rev Chg LTM | -0.2% |
| Op Mgn LTM | -24.3% |
| Op Mgn 3Y Avg | -38.3% |
| QoQ Delta Op Mgn LTM | 2.4% |
| CFO/Rev LTM | 9.3% |
| CFO/Rev 3Y Avg | -16.2% |
| FCF/Rev LTM | 5.1% |
| FCF/Rev 3Y Avg | -21.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.7 |
| P/S | 1.6 |
| P/EBIT | -2.9 |
| P/E | -2.9 |
| P/CFO | 3.5 |
| Total Yield | -20.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -38.0% |
| D/E | 0.3 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.4% |
| 3M Rtn | -24.7% |
| 6M Rtn | -37.9% |
| 12M Rtn | -35.7% |
| 3Y Rtn | -73.2% |
| 1M Excs Rtn | -0.5% |
| 3M Excs Rtn | -17.0% |
| 6M Excs Rtn | -34.5% |
| 12M Excs Rtn | -50.8% |
| 3Y Excs Rtn | -136.7% |
Price Behavior
Price Behavior
| Market Price | $8.11 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/09/2013 | |
| Distance from 52W High | -53.3% | |
| 50 Days | 200 Days | |
| DMA Price | $10.26 | $11.51 |
| DMA Trend | down | down |
| Distance from DMA | -20.9% | -29.6% |
| 3M | 1YR | |
| Volatility | 85.6% | 2,040.1% |
| Downside Capture | -0.16 | 2.72 |
| Upside Capture | -171.19 | 278.52 |
| Correlation (SPY) | -12.7% | 2.2% |
DRIO Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.00 | 0.10 | 0.03 | 0.56 | 2.36 | 1.81 |
| Up Beta | -1.56 | 0.48 | 0.31 | 1.16 | -4.53 | -1.61 |
| Down Beta | 0.35 | 0.32 | 0.97 | 2.26 | 1.06 | 1.27 |
| Up Capture | 103% | 39% | -49% | 7% | 1197% | 155% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 10 | 19 | 30 | 56 | 113 | 344 |
| Down Capture | -40% | -86% | -66% | -84% | 170% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 10 | 20 | 27 | 64 | 132 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DRIO | |
|---|---|---|---|---|
| DRIO | -35.4% | 2,032.0% | 0.94 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | -2.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 2.2% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 2.4% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 3.5% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | -1.1% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 3.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DRIO | |
|---|---|---|---|---|
| DRIO | -55.5% | 909.9% | 0.38 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 0.2% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 2.9% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 2.4% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 2.2% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 1.0% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 2.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DRIO | |
|---|---|---|---|---|
| DRIO | -40.5% | 646.7% | 0.28 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 1.2% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 3.2% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 2.5% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 2.1% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 1.8% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 1.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/24/2023 | -12.8% | -11.6% | -35.7% |
| 2/6/2023 | 10.5% | 8.2% | -5.1% |
| 8/15/2022 | -5.9% | -31.6% | -42.6% |
| 1/19/2022 | -3.3% | -13.7% | -11.6% |
| 8/16/2021 | -12.3% | -5.1% | 5.6% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 4 | 4 | 4 |
| Median Positive | 10.5% | 8.2% | 5.6% |
| Median Negative | -9.1% | -12.7% | -23.7% |
| Max Positive | 10.5% | 8.2% | 5.6% |
| Max Negative | -12.8% | -31.6% | -42.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/10/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nelson, Steven Charles | President and CCO | Direct | Buy | 8272025 | 0.53 | 40,000 | 21,200 | 50,350 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.